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Abstract NY-ESO-1 and LAGE-1 are cancer testis
antigens with an ideal profile for tumor immunotherapy,
combining up-regulation in many cancer types with highly
restricted expression in normal tissues and sharing a
common HLA-A*0201 epitope, 157–165. Here, we present
data to describe the specificity and anti-tumor activity of a
bifunctional ImmTAC, comprising a soluble, high-affinity
T-cell receptor (TCR) specific for NY-ESO-1157–165 fused
to an anti-CD3 scFv. This reagent, ImmTAC-NYE, is
shown to kill HLA-A2, antigen-positive tumor cell lines,
and freshly isolated HLA-A2- and LAGE-1-positive
NSCLC cells. Employing time-domain optical imaging, we
demonstrate in vivo targeting of fluorescently labelled
high-affinity NYESO-specific TCRs to HLA-A2-, NY-
ESO-1157–165-positive tumors in xenografted mice. In vivo
ImmTAC-NYE efficacy was tested in a tumor model in
which human lymphocytes were stably co-engrafted into
NSG mice harboring tumor xenografts; efficacy was
observed in both tumor prevention and established tumor
models using a GFP fluorescence readout. Quantitative
RT-PCR was used to analyze the expression of both NY-ESO-1
and LAGE-1 antigens in 15 normal tissues, 5 cancer cell lines,
10 NSCLC, and 10 ovarian cancer samples. Overall, LAGE-1
RNA was expressed at a greater frequency and at higher levels
than NY-ESO-1 in the tumor samples. These data support the
clinical utility of ImmTAC-NYE as an immunotherapeutic
agent for a variety of cancers.
Keywords Bi-specific TCR  ImmTAC  Cancer
immunotherapy  NY-ESO-1  LAGE-1  Time-domain
Introduction
Understanding of anti-tumor immunity has increased sig-
nificantly over the past decade, including fundamental
insights into the role of innate and adaptive immune
responses in targeting and eliminating tumors [1, 2]. In
both animal studies and, more recently, clinical studies,
CD8? cytotoxic T cells (CTLs) have been shown to be
major effector cells involved in the eradication of tumor
cells [3–5]. A requisite step for the targeting of tumors by
CTL is the binding of T-cell receptors (TCRs) to peptides
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derived from the proteome of tumors and presented on the
cell surface in the context of MHC Class I molecules
(pMHCs) [6]. A major limitation for the effective targeting
of established tumors by T cells results from central tol-
erance, whereby T cells with strong affinity for self-anti-
gens are deleted in the thymus [7]. In addition, the natural
selection process inherent in the growth and establishment
of tumors in immune-competent hosts leads to the selection
of tumors with decreased antigen and MHC expression and
alterations in antigen processing and presentation, reducing
the surface density of pMHC complexes [8]. Finally,
peripheral tolerance mediated through host and tumor-dri-
ven immunosuppressive mechanisms contributes to the
ultimate inability to mount an effective T-cell immune
response to target tumors [9–11].
One approach to overcome the lack of potent anti-tumor
T-cell immunity is the ex vivo genetic modification of T cells
to target tumors through the use of affinity-enhanced recep-
tors generated from either T cell or antibody-derived recep-
tors; recent clinical data have provided evidence that such
approaches hold significant clinical promise [12, 13]. A
complementary approach that does not require ex vivo
manipulation of T cells involves the use of fusion proteins
that combine tumor recognition and T cell engaging domains
to redirect T cells to target tumors [14]. Among this class of
reagents are several monoclonal antibody-anti CD3 scFv
fusion reagents, some of which have undergone clinical
evaluation with strong evidence of efficacy [14–17]. The use
of antibody-based T-cell targeting agents is restricted to tar-
geting of antigens expressed on the cell surface. To overcome
this limitation, we have recently developed a class of
bi-specific fusion protein reagents termed ImmTACs (Immune-
mobilizing monoclonal TCRs against Cancer), which target
proteosomally processed epitopes derived from intracellular,
surface bound, and secreted antigens [18]. ImmTACs are
comprised of soluble, high-affinity (pico-Molar) monoclonal
TCRs (mTCRs) specific for antigen-derived pMHC com-
plexes, combined with a humanized anti-CD3 scFv domain,
which activates a potent anti-tumor T-cell response. The first
clinical candidate ImmTAC product, IMCgp100, specific for
gp100280–288 is currently undergoing Phase I clinical testing in
melanoma patients (trial number NCT01211262).
NY-ESO-1 (CT6, also known as LAGE-2) and LAGE-1
are among the prototypic cancer testis antigens [19, 20].
Although little is known about their functions, normal
tissue expression of both of these antigens is principally
limited to immune privileged sites [20–22]. Like other CT
antigens, both NY-ESO-1 and LAGE-1 are expressed
during development as well as by a wide range of tumors
including myeloma [23, 24] and a variety of solid tumors
such as ovarian [25], non-small-cell lung cancer (NSCLC)
[26, 27], and melanoma [28, 29]. NY-ESO-1 has been
targeted extensively in clinical trials using a variety of
approaches including vaccines and gene-modified T cells
[13, 30]. Multiple studies have demonstrated that NY-ESO-1
is antigenic in human patients [21, 31], although vaccina-
tion approaches alone rarely lead to a clinically significant
response [32, 33].
We have previously described both a high-affinity mTCR
and ImmTAC reagent (ImmTAC-NYE) specific for the
immunogenic HLA-A2 presented peptide NY-ESO-1157–165
(SLLMWITQC) [18, 34]. Notably, since the same epitope is
processed from the LAGE-1 antigen [20, 35], ImmTAC-
NYE can be used to redirect T cells against HLA-A*0201-
positive tumors that express either NY-ESO-1 or LAGE-1
antigens. In this report, we demonstrate that ImmTAC-NYE
redirects potent antigen-restricted T-cell activity against NY-
ESO-1- and/or LAGE-1-positive tumors, including estab-
lished cell lines shown previously to present low levels of
cell surface epitope [34] and primary lung cancer cells. We
show in vivo targeting of high-affinity NYE TCR to tumors
presenting the NY-ESO epitope via time-domain optical
imaging of fluorescently labelled mTCR. Importantly, we
demonstrate ImmTAC-NYE-mediated inhibition of tumor
growth in vivo, in a model co-xenografted with both human
peripheral blood lymphocytes and cancer cells. The results
provide rationale to support the further preclinical and clin-
ical development of ImmTAC-NYE as a bi-specific immu-
notherapeutic agent to treat HLA-A*0201-positive and NY-
ESO-1- and/or LAGE-1-expressing solid cancers.
Materials and methods
Human tissues, cells, and cell lines
Primary tumor tissue from lung and ovarian cancer patients
was collected at the University of Pennsylvania under an
IRB approved protocol. Pathologic review of biopsies
confirmed diagnosis in each case. Tumor biopsies were
processed as described [36] to obtain single-cell suspen-
sions which were viably frozen.
Cell lines J82 (urothelial), SK-Mel-37, Mel526, Mel624,
A375 (melanoma), IM9 (EBV B), and U266 (multiple
myeloma) were obtained from American Type Culture
Collection or as described previously [34] and cultured in
R-10 medium. Cell lines were acquired between 2004 and
2010; HLA genotype and/or phenotype and expression of
various cancer-associated antigens were confirmed by
DNA sequencing, RT-PCR, and antibody staining, and
lines displayed phenotypic characteristics of the tumor of
origin. HEP2, HA2, and CM12 (normal human cells grown
in culture) were purchased from ScienCell and NHEM10
cells from PromoCell.
Construction of J82-NY-ESO157–165 and SK-Mel-37-
NY-ESO157–165 minigene-transfected cell lines has been
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described previously (as SLLMWITQC-minigene trans-
fectants) [34].
J82-NY-ESO157–165 cells stably expressing enhanced
green fluorescent protein (EGFP) (Clontech Laboratories,
Inc., Mountain View, CA) were engineered using the
pCGFP retroviral vector [37]. Production of infectious ret-
roviral vector particles in Phoenix A cells and infection of
cells were carried out as described [38]. This procedure was
repeated twice, producing cells expressing high levels of
GFP as determined by fluorescence microscopy (Leica
Microsystems, GmbH, Wetzlar, Germany). The 5 %
brightest cell population was isolated by a modified
FACSAria II flow cytometer (BD BioSciences).
Peripheral blood lymphocytes (PBLs) were obtained
from human healthy volunteers following Ficoll-Hypaque
density gradient separation (Lymphoprep, Nycomed
Pharma AS, Oslo, Norway).
Magnetic bead immunodepletion (Dynal) removed
CD19?, CD4?, and CD14? cells to obtain CD8? ve
T-cell populations.
Quantitative RT-PCR on normal and neoplastic human
cells
RNA was isolated from viably frozen specimens or cell
lines growing in logarithmic phase using RNAqueous-4
PCR kits (Ambion corp, AM1914). cDNA was synthesized
using iScript cDNA synthesis kits (Biorad Corp,
170-8891). qRT-PCR analysis was performed using
standard Taqman—MGB technology and amplification
conditions using an ABI 7500 FAST instrument (ABI-Life
technologies), and the following ABI inventoried primer-
probe sets: NY-ESO-1: HS00265824_m1; LAGE-1:
HS00535628_m1; Gus-B: HS99999908_m1; b-Actin:
HS99999903_m1. Amplifications were performed in trip-
licate; individual Ct values were determined (minimum of
2/3 replicates with % CV \ 15 %) and average values
reported. RQ (relative quantification) values for NY-ESO-1
and LAGE-1 transcripts were determined according to the
formula RQ = 2-DDCt, with DDCt = DCtsample - DCtref-
erence, with DCtsample = Ctsample - Ctsample normalizer and
DCtreference = Ctreference - Ctreference normalizer [39]. For
all analyses, the melanoma cell line A375 (positive for
NY-ESO-1 and LAGE-1) served as a reference; either Gus-B
or b-Actin (for a subset of analyses) was used as the normal-
izer ‘‘housekeeping’’ gene.
Engineering high-affinity TCRs and bi-specific
ImmTACs
TCR isolation and engineering to produce ImmTAC
reagents has been described previously [18, 40].
Cytotoxicity and cytokine release assays
Cytotoxicity (LDH release) and IFNc ELISpot assays were
performed as previously described [18]. Multiple cytokine
release (TNFa, IFNc, and IL-2) was measured by Meso
Scale Discovery (MSD) immunoassay following overnight
incubation of CD8? effector T cells and targets at a 1:1
ratio in the presence of 1 nM ImmTAC-NYE, in accor-
dance with manufacturer’s instructions.
IncuCyte and real-time quantification of cell killing
Target tumor cells were incubated with effector CD8? T cells
(5:1 E:T) in the presence or absence of ImmTAC-NYE. Ima-
ges were taken every 10 min and the number of apoptotic cells
per mm2 was quantified using the CellPlayer 96-well Kinetic
Caspase 3/7 reagent and the IncuCyte-FLR-Platform (Essen
Biosciences). The reagent is cleaved by activated Caspase 3/7
upon target cell apoptosis resulting in the release of the dye and
green fluorescent staining of nuclear DNA. The cocktail of
apoptotic drugs used as a positive control contains 10 lM
stausporine, 2 lg/ml anisomycin, and 10 lM etoposide.
TCR fluorescence labelling
TCR-NYE-wt, TCR-NYE-(29 nM), and TCR-NYE-
(0.048 nM) were labelled with Alexa Fluor 680 carbox-
ylic acid, succinimidyl ester as previously described [41].
Labelling was restricted to 2 fluors per molecule. Protein
concentration and degree of labelling were determined by
spectrophotometric analysis using a NanoDrop spectro-
photometer (Thermo Scientific, Rockford, USA).
Animal studies
Animal experiments were approved by The Norwegian
Animal Research Authority and performed in accordance
with the European Convention for the Protection of Verte-
brates Used for Scientific Purposes. NOD-scid and NOD-
scid IL2rcnull (NSG) mice (6–8 weeks old) were originally
a gift of Prof. L. Shultz, Jackson Laboratories, Bar Harbour,
USA, and were bred at the Gades Institute, University of
Bergen. 5 9 106 tumor cells were injected subcutaneously
(s.c.) in a solution of PBS/Matrigel (1:1) bilaterally in flanks
of mice (n = 2 per mouse). Tumor volumes were measured
by digital calliper measurements using the formula: Vol-
ume = p (length 9 width 9 height)/6. Blood samples
(100 lL) were acquired by submandibular bleeding.
TCR imaging studies
When J82-NY-ESO157–165 tumors reached an average vol-
ume of 100–150 mm3, background fluorescence images
of the mice (n = 4 per group) were acquired prior to
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intravenous (i.v.) injection with Alexa680 labelled TCRs
(0.6 mg/kg) at 0 h and the mice imaged for TCR fluorescence
at 4, 8, 24, 48, and 96 h.
Tumor protection study in mice harboring human PBL
xenografts
NSG mice were inoculated i.v. with 20 9 106 human PBLs
and randomized into study groups (equally distributed per
percentage hu-CD45?CD3?). When mice demonstrated at
least 10 % hu-CD3? cells by flow cytometry (approx. week
3), SK-Mel-37-NY-ESO157–165 cells [34] were injected s.c.
and mice treated i.v. with either ImmTAC-NYE (0.04 mg/
kg, Q.D.) or PBS (equivalent volume) on days 1–5.
ImmTAC efficacy studies in mice harboring cancer
and human PBL xenografts
When J82-NY-ESO157–165
GFP tumors reached 50 mm3, 20 9 106
human PBL per mouse were injected i.v. After mice dem-
onstrated engraftment of human lymphocytes (at least 10 %
hu-CD3? cells) and tumor volumes reached 100–150 mm3,
they were imaged for GFP fluorescence and randomized into
study groups. Mice were then treated with ImmTAC-NYE,
control ImmTAC-GAG (0.04 mg/kg, Q.D., i.v.), or PBS
(equivalent volume, i.v.) for days 1–5 and tumors monitored
weekly by time-domain optical imaging. The study was ter-
minated 25 days following the first ImmTAC treatment.
Optical imaging
Time-domain optical imaging was performed with Optix
MX2 (ART Inc., Saint-Laurent, QC, Canada) as described
previously [42]. Fluorescence images were acquired and
analyzed with Optix OptiviewTM (version 2.00; ART
Inc.) and Optix OptiviewTM (version 2.02.00, ART Inc.).
Flow cytometric analysis of blood
Peripheral blood cells were analyzed by FACSCanto II (BD)
using mouse anti-huCD3 (PE conjugate; clone SK7) and hu
CD45 (FITC conjugate; clone 2D1) monoclonal antibodies (BD
Immunocytometry). Human T-cell engraftment in peripheral
blood was defined as the percentage of huCD45?CD3? mono-
nuclear cells (MNCs) in murine peripheral blood.
Results
Expression of NY-ESO-1 in normal and in neoplastic
cells and tissues
We evaluated the expression of NY-ESO-1 and LAGE-1 in
a panel of normal tissues and established cell lines, as well
as a panel of primary tumor material from lung and ovarian
cancer patients using quantitative real-time PCR. With the
exception of low level LAGE expression in one normal
tissue sample (SMC3), we did not detect transcripts for
either NY-ESO-1 or LAGE-1 in 15 HLA-A2? normal
tissue cells, including melanocytes, hepatocytes, astrocytes,
endothelial cells (aortic and dermal microvascular), fibro-
blasts (dermal and pulmonary), and epithelial cells (renal
and ciliary) (Supplementary Table 1). Both NY-ESO-1 and
LAGE-1 were broadly expressed at various levels and
across a large number of tumor cell lines, including mel-
anoma, myeloma, mesothelioma, lung, ovarian, and pros-
tate cancer; among the tumor cell lines tested, only the
colon cancer cell line Colo205 and the colorectal carci-
noma HCT116 were negative for both antigens (Table 1
and Supplementary Table 2).
We further evaluated the expression of NY-ESO-1 and
LAGE-1 in primary tumor specimens from ten NSCLC and
ten ovarian cancer patients (Table 1). In NSCLC speci-
mens, NY-ESO-1 and LAGE-1 transcripts were detected in
3 of 10 samples. In the ovarian cancer specimens, NY-
ESO-1 was detected in 6 of 10 and LAGE-1 in 8 of 10
ovarian cancer specimens. NY-ESO-1 and LAGE-1
expression was not always concordant. Notably, as asses-
sed by average Ct values, in some cases (NSCLC-#81,
ovarian #23, #96), LAGE-1 mRNA was expressed at sig-
nificantly higher levels than NY-ESO-1. Overall, 30 % of
the NSCLC samples and 80 % of the ovarian specimens
were positive for one or both antigens.
Short-term redirected T-cell killing of NY-ESO-1
tumor-derived cell lines by ImmTAC-NYE
ImmTAC-NYE has a binding affinity in the low pico-
Molar range (approximately 50 pM) with a binding
half-life of several hours; it has previously been shown to
target two NY-ESO-1-/LAGE-1-positive tumor lines and
activate T cells resulting in redirected killing [18]. The
affinity-enhanced TCR is completely specific for the NY-
ESO157–165 epitope presented by HLA-A*0201 demon-
strating that specificity has not been lost during engineering
(Supplementary Table 3). The ability of ImmTAC-NYE to
redirect killing of additional HLA-A2*0201?, NY-ESO-1/
LAGE-1? tumor cell lines over 24 h was assessed by
measuring LDH release from the target cells. Figure 1a
shows a dose titration of ImmTAC-NYE in the presence of
target tumor cells and CD8? effector T cells. With the
exception of the SK-Mel-37 cells, dose-dependent lysis of
all the target cells was detected. No lysis was detected in
the absence of ImmTAC-NYE. Figure 1b shows that
ImmTAC-NYE induces the secretion of multiple cytokines
(TNFa, IFNc, and IL-2) from T cells in response to the
IM9 cell line (NY-ESO-1/LAGE-1 high).
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ImmTAC-NYE activates T cells in the presence
of freshly isolated tumor cells
To confirm that ImmTAC-NYE recognizes freshly isolated
tumor cells in addition to tumor cell lines, we measured
T-cell activation in response to lung cancer sample
NSCLC#29, which expresses high levels of LAGE-1
(Table 1). Figure 1c shows that IFNc is released from CD8
T cells in the presence of NSCLC#29 and ImmTAC-NYE,
with a similar potency to redirected killing of tumor cell
lines. Insufficient numbers of tumor cells were isolated to
carry out a killing assay.
ImmTAC-NYE is specific for its target peptide
The specificity of ImmTAC-NYE was investigated using
HLA-A2*0201?, NY-ESO-1-/LAGE-1-negative primary
human cells derived from normal tissues. The LDH release
assay data shown in Fig. 1d demonstrate the lack of lysis of
hepatocytes, cardiac myocytes, and melanocytes by con-
centrations of ImmTAC-NYE up to 1 nM; at 10 nM, a low
level of lysis is observed. We have observed a slight loss of
epitope specificity at high concentrations (10 nM and
above) with other HLA-A2-specific ImmTACs, which is
HLA-A2-dependent ([18] and unpublished data).
Direct visualization of redirected tumor cell killing
mediated by ImmTAC-NYE
Killing of tumor cell lines over longer time periods was
investigated using IncuCyte-FLR technology, enabling
visualization of caspase 3/7-dependent apoptosis by
microscopy at 37 C in real time. Target tumor cells were
incubated with effector CD8? T cells in the presence or
absence of ImmTAC-NYE and images taken at intervals of
10 min. The killing time course for SK-Mel-37 cells
(HLA-A2*0201?, LAGE-1?), a cell line relatively resis-
tant to lysis after 24 h (see Fig. 1a) is shown in Fig. 2a) in
the presence of 0.1 nM and 1 nM ImmTAC-NYE. In
agreement with the LDH assay (Fig. 1a), no significant
killing was observed after 24 h. However, many apoptotic
cells were present at 72 h, indicating that for some target
cells (e.g., those that are resistant to lysis or with very low
epitope levels), ImmTAC-NYE-induced killing requires in
excess of 24 h. Figure 2b shows the killing time courses
for Mel624 cells, again indicating that cell death occurs
mainly after 24 h; the images taken at 48 h (Fig. 2h–i)
confirm that close to 100 % of the cells have been killed at
this time point. Figure 2c shows killing time courses for
normal kidney epithelial cells (REN2) incubated with 0.1
and 1 nM ImmTAC-NYE over 72 h, confirming that nor-
mal cells are not killed in response to the ImmTAC even
after 3 days. This is the first reported use of IncuCyte-FLR
technology to measure CTL activity.
In vivo imaging of tumors by soluble NY-ESO-specific
TCRs
In vivo tumor targeting of NY-ESO-1 antigen was visual-
ized using Alexa-fluor 680 labelled un-fused TCRs (rather
than ImmTAC fusion proteins) in a xenograft model of
J82-NY-ESO157–165, a human bladder cell line engineered
to express the NY-ESO157–165 epitope [34]. Three TCRs
were employed, all binding specifically to this epitope but
differing in affinity: a) the wild-type TCR-NYE-wt, b)
medium-affinity TCR-NYE-(29 nM), and c) high-affinity
Table 1 Expression of NY-ESO-1 and LAGE-1 transcripts in primary
NSCLC and ovarian cancer specimens, and in selected tumor cell lines
Tumor type Sample
ID
Gus-B NY-ESO-1 LAGE-1
Avg. Ct Avg.
Ct
RQ Avg.
CT
RQ
Primary tumor samples
Melanoma A375 26.4 26.0 1 35.6 1
NSCLC #25 24.1 ND ND ND ND
NSCLC #28 28.5 ND ND ND ND
NSCLC #29 26.5 27.0 0.54 28.7 127.3
NSCLC #30 23.6 25.9 0.16 25.5 155
NSCLC #31 24.9 ND ND ND ND
NSCLC #35 26.2 ND ND ND ND
NSCLC #79 28.3 ND ND ND ND
NSCLC #81 26.0 38.3 0.0002 32.6 6.27
NSCLC #93 22.9 ND ND ND ND
NSCLC #95 24.4 ND ND ND ND
Ovarian #23 24.8 37.3 0.0001 28.5 46.2
Ovarian #61 24.8 ND ND 35.8 0.22
Ovarian #65 25.8 39.0 0.0001 39.4 0.06
Ovarian #79 20.1 35.2 0.014 35.2 0.017
Ovarian #86 20.7 37.3 0.00001 38.5 0.0032
Ovarian #90 22.9 37.5 0.00003 37.8 0.02
Ovarian #91 23.4 ND ND 38.3 0.024
Ovarian #96 22.7 32.7 0.0008 24.7 159
Ovarian #99 31.9 ND ND ND ND
Ovarian #103 24.3 ND ND ND ND
Tumor cell lines
Melanoma
(reference)
A375 24.8 23.35 1 33 1
Melanoma SK-Mel-
37
23.8 38.4 0.00002 37.0 0.03
EBV
transformed
B cell from
myeloma pt
IM9 23.3 25.2 0.10 23.9 195.3
Melanoma
(reference)
A375 18.9* 22.1 1.000 31.2 1.000
Melanoma Mel526 16.9* 37.2 0.00001 32.2 0.09
Multiple
myeloma
U266 17.3* 20.2 1.2 21.2 311.8
ND not detected
* b-actin used as housekeeping gene
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TCR-NYE-(0.048 nM); the affinities of the engineered
TCRs are indicated in brackets, that is, 29 nM and 48 pM.
Time-domain optical imaging of engrafted tumors was
performed at intervals following administration of Alexa
680 labelled TCRs. The resulting images (Fig. 3a) were
gated for fluorescence lifetimes of the TCR-Alexa 680
conjugates facilitating the distinction of specific mTCR-
targeted fluorescence from background fluorescence. Mice
inoculated with TCR-NYE-wt exhibited only transient
tumoral fluorescence at the 4- and 8-h imaging time points
before a return to background fluorescence levels at 48 h
(Fig. 3b, c). Imaging of TCR-NYE-(29 nM)-treated mice
demonstrated a similar pattern, although fluorescence
intensities were higher (24 and 48 h) than those observed
for the TCR-NYE-wt-treated mice. Only with mice injec-
ted with Alexa 680 labelled high-affinity TCR-NYE-
(0.048 nM) were higher than background fluorescence
levels observed throughout the time course; significantly,
higher fluorescence intensities were noted in these mice at
24 and 48 h (p \ 0.05), and even at 96 h, intensities were
2.5 times higher than background.
ImmTAC-NYE therapy prevents the growth of NY-
ESO epitope? tumors in a xenografted mouse model
The evaluation of immuno-therapeutic agents in immuno-
deficient preclinical models typically requires subcutane-
ous (s.c.) co-injection of cancer and T cells or repeated
injections [s.c. or intravenous (i.v.)] of high numbers of T
cells in mice with pre-established tumors. However, these
assays do not accurately reflect the potential of endogenous
T cells to target cancer cells; for example, imaging studies
over 4 days from the time of injection of T cells into
tumor-bearing mice reported that less than 1 % of i.v.
injected T cells home to tumors [42]. Recent studies have
demonstrated the NSG mouse model to be sufficiently
(a) (c)
(b) (d)
Fig. 1 Activation and killing by ImmTAC-NYE redirected T cells
against NY-ESO-1/LAGE-1 tumor-derived cell lines and freshly
isolated tumor cells. a Redirected lysis of HLA-A2?, NY-ESO-1/
LAGE? tumor cell lines (as indicated in the figure key) by ImmTAC-
NYE with purified CD8? effector T cells. Controls: effectors and
targets in the absence of ImmTAC-NYE, with the open symbol shapes
matching the target cells indicated in the figure key. SK-Mel-37 cells
present an average of 25 epitopes per cell, Mel624 cells an average of
45 and U266 cells an average of 5–10. b ImmTAC-NYE induces
multiple cytokine release (TNFa, IFNc, and IL-2) from CD8? T cells
in response to NY-ESO-positive IM9 cells; control cells are Mel526
(NY-ESO low). c IFNc release from PBMCs in response to ImmTAC-
NYE and freshly isolated LAGE-1? lung cancer sample NSCLC#29
measured by ELISpot; Colo205 cells (antigen negative, HLA-A2?)
are the specificity control. Open symbols represent targets and
effectors without ImmTAC-NYE, with the symbol shapes matching
the target cells indicated in the figure key. d ImmTAC-NYE does not
lyse HLA-A2?, NY-ESO-1-/LAGE-1-negative primary human cells
derived from normal tissues and expanded in culture. Purified CD8?
T cells were incubated with hepatocytes (HEP2), astrocytes (HA2),
melanocytes (NHEM10), and cardiac myocytes (CM12) in the
presence of 0.1, 1, and 10 nM ImmTAC-NYE. Antigen-positive
U266 cells were included as a positive control. In a and d, lysis was
determined by LDH release from target cells after 24 h, with an E:T of
10:1; error bars depict mean values ± SEM
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immunodeficient to permit the xenografting of functional
immune systems [43]. Thus, we investigated whether this
host would permit co-engraftment of both cancer cell lines
and hu-PBLs, in order to develop a model in which the
efficacy of ImmTAC-NYE can be evaluated in vivo. NSG
mice were inoculated with hu-PBLs, and flow cytometry
analyses showed the presence of robust populations of hu-
CD45?CD3? cells in xenografted recipients from week 3,
with all mice exhibiting a hu-CD45?CD3? cell population
of at least 10 % of total peripheral blood lymphocytes.
SK-Mel-37-NY-ESO157–165 cells were injected subcutane-
ously and treatment with either ImmTAC-NYE or PBS was
initiated on the same day (Fig. 4a, b); a total of five doses
of ImmTAC-NYE were administered.
While the tumors in PBS-treated mice underwent pro-
gressive growth with average volumes reaching 368 mm3
by day 50, palpable tumors were only just evident in the
ImmTAC-NYE-treated mice at this time point (Fig. 4c;
p \ 0.001). Furthermore, once these tumors had been
established, they developed with demonstrably slower
growth kinetics only reaching average tumor volumes of
141 mm3 3 months after treatment (data not shown).
ImmTAC-NYE therapy targets established J82-NY-
ESO157–165
GFP tumors in mice engrafted with human
PBMC
Having demonstrated in vivo targeting of TCR-NYE to
J82-NY-ESO157–165 cells and tumor prevention by
ImmTAC-NYE in a xenograft model harboring both
SK-Mel-37-NY-ESO157–165 cells and hu-CD45
?CD3?
T-cell populations, we sought to evaluate anti-tumor efficacy
of ImmTAC-NYE using optical imaging in pre-established
tumors. J82-NY-ESO157–165
GFP cells were injected s.c. into the
flanks of NSG mice, and when the tumors reached
approximately 50 mm3, mice were inoculated with hu-PBL
Fig. 2 Target cell apoptosis induced by ImmTAC-NYE redirected T
cells measured in real time. a SK-Mel-37, b Mel624 melanoma cells,
or c REN2 normal renal epithelial cells were incubated with CD8?
cells in the presence or absence of ImmTAC-NYE and images taken at
10-min intervals. In c REN2, cells were also treated with a cocktail of
drugs to induce apoptosis (apoptosis cocktail) to control for the
presence of live cells. Representative end point images are shown for
SK-Mel-37 (d–f, 72 h) and Mel624 (g, h, i 48 h) targets at the
indicated concentrations of ImmTAC-NYE. White flashes marked
with red-crosses represent cells undergoing apoptosis and are
recorded as objects. Control: effectors and targets in the absence of
ImmTAC-NYE
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(Supplementary Figure 1). When recipient mice demon-
strated at least 10 % T-cell chimerism (Supplementary
Table 4) and tumor volumes of 100–150 mm3 (PBS,
124.9 ± 23.8 mm3; ImmTAC-GAG, 133.5 ± 25.8 mm3;
ImmTAC-NYE 136.6 ± 4.7 mm3; one-way ANOVA
p = 0.98), they were treated with ImmTAC-NYE (0.04 mg/
kg), control ImmTAC-GAG (specific for an HLA-A2 pre-
sented HIV epitope) (0.04 mg/kg) or PBS for 5 days, and
tumor viability monitored by fluorescence imaging (Sup-
plementary Figure 2). Treatment of control groups with
either ImmTAC-GAG or PBS did not affect the tumor
growth of the J82-NY-ESO157–165
GFP cells as demonstrated by
GFP fluorescence intensity (Fig. 5a, b). In contrast, mice
treated with ImmTAC-NYE exhibited significantly reduced
GFP fluorescence on Day 7 when compared with pre-treat-
ment Day 0 fluorescence and ImmTAC-GAG or PBS con-
trols on Day 7 (p \ 0.001). By days 14 and 21, the GFP
fluorescence intensity values of J82-NY-ESO157–165
GFP tumors
in ImmTAC-NYE-treated mice increased from day 7 nadirs
but remained significantly lower than either of the control
groups (p \ 0.01).
Discussion
The current study was performed to investigate the utility
of a bi-specific ImmTAC reagent targeting an epitope
common to both NY-ESO-1 and LAGE-1 for cancer
immunotherapy. The expression patterns of both NY-ESO-
1 and LAGE-1 in tumors identify these proteins as suitable
targets for the treatment of a wide variety of malignancies.
NY-ESO-1 and LAGE-1 are members of the cancer testis
class of tumor-associated antigens, which has the ‘‘clean-
est’’ expression profile in normal tissue. Since these anti-
gens are intracellular, they are not accessible to
conventional therapeutic antibodies and targeting of MHC-
presented peptide epitopes provides an opportunity for
tumor-directed immunotherapy [35, 44].
RT-PCR studies have detected NY-ESO-1 or LAGE-1
transcripts in the testis, placenta, and ovary; other normal
human tissues completely lacked expression, with the
exception of one qRT-PCR study which also identified low
levels of NY-ESO-1 mRNA in liver and pancreas [20, 22,
45]. In broad agreement with previous data, qRT-PCR
Fig. 3 TCR-Alexa 680 targeting studies. a Mice xenografted with
J82-NY-ESO157–165 cells were injected with Alexa 680 labelled TCR
and analyzed at intervals using time-domain optical imaging. Images
were then gated for the fluorescence lifetime of TCR-Alexa 680
and TCR-Alexa 680 photons quantified. b Representative gated
fluorescence images of mice injected with TCR-NYE-wt, TCR-NYE-
(29 nM), and TCR-NYE-(0.048 nM) over the time course. Fluores-
cence scale is the same for all mice. c Histogram of gated fluorescence
normalized on 4-h results. Error bars present SEM. *p \ 0.05
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analyses performed in the current study did not detect NY-
ESO-1 or LAGE-1 transcripts in several normal human
tissues including hepatocytes, melanocytes, and a range of
fibroblasts and endothelial cells derived from different
organs. In contrast, NY-ESO-1 and/or LAGE-1 transcript
expression was detected not only in cell lines derived from
a variety of tumor types but also in primary tumors of
ovarian cancer and NSCLC. In agreement with other
studies [25, 35, 46, 47], there was general overlap in NY-
ESO-1 and LAGE-1 mRNA expression, although a subset
Fig. 4 Tumor protection study in mice harboring human PBL xeno-
grafts. a, b Human PBL-engrafted mice were injected subcutaneously
with SK-Mel-37-NY-ESO157–165 cells and treated intravenously with
ImmTAC-NYE (n = 6) or PBS (n = 6) days 1–5. c Tumor volumes
plotted against time. Error bars present SEM. ***p \ 0.001
Fig. 5 ImmTAC efficacy study in mice co-xenografted with human
PBL and J82-NY-ESO157–165
GFP cells. a GFP gated fluorescence time
course of representative mice xenografted with human PBL and J82-
NY-ESO157–165
GFP cells and treated with ImmTAC-GAG (n = 4),
ImmTAC-NYE (n = 4), or PBS (n = 4). b Average fold change in
GFP-gated fluorescence for all animals over the time course. Asterisks
indicate unpaired Student’s t test statistical analysis of the difference
in GFP-gated fluorescence of ImmTAC-NYE- and ImmTAC-GAG-
treated mice. Error bars present SEM. *p \ 0.05, **p \ 0.01,
***p \ 0.001
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of samples was identified which expressed only one of the
antigens (Table 1). Particularly for the ovarian cancer
specimens, LAGE-1 expression was detected at higher
RNA levels and at a greater frequency than NY-ESO-1,
suggesting that LAGE-1 may be a superior target antigen
for cancer immunotherapy in at least some tumor types.
Andrade et al. [24] made a similar observation in multiple
myeloma (49 % LAGE-1 vs. 33 % NY-ESO). A previous
study detected presentation of the NY-ESO-1157–165 epi-
tope by the SK-Mel-37 and Mel 624 cell lines [34], which
express far higher levels of RNA for LAGE-1 than for NY-
ESO-1 (Table 1), confirming that this peptide can be pro-
cessed efficiently from LAGE-1.
We have engineered three soluble mTCRs specific for
the NY-ESO-1157–165 epitope, TCR-NYE-wt (the wild-type
affinity TCR), and two affinity matured variants TCR-
NYE-(29 nM) and TCR-NYE-(0.048 nM). Since previous
studies have shown the importance of mTCR affinity for
ImmTAC potency [18], the highest affinity ImmTAC-NYE
was evaluated in vitro and in vivo. ImmTAC-NYE was
able to activate and redirect normal CD8? T cells to a
range of cell lines derived from melanoma (A375, Mel624,
and SK-Mel-37), myeloma (U266), and EBV transformed
B cells (IM9), in addition to freshly isolated lung cancer
cells. The demonstration that the redirected cell lysis was
limited to those cells expressing endogenous NY-ESO-1
and/or LAGE-1 proteins [34] was essential to exclude the
possibility of non-specific toxicity against normal tissues in
a clinical setting. While significant lysis of the majority of
the tumor cell lines occurred during the first 24 h, the In-
cuCyte real-time imaging system demonstrated that some
cell lines required longer periods for caspase 3/7-dependent
apoptosis to occur. One possible explanation for the
observed variation in cell lysis is the difference in density
of target epitopes on the surface of each cell line; previous
studies using TCR-NYE-(0.048 nM) reported the presence
of 25 and 45 epitopes/cell on the SK-Mel-37 and Mel624
cell lines respectively [34], and U266 cells have 5–10
epitopes per cell (unpublished data). Other factors which
may influence the rate of cell killing are firstly suscepti-
bility of individual tumor cell lines to lysis and secondly
the presence of cofactors such as CD80 and CD86 on the
tumor cells which may augment killing.
An essential element for the efficacy of targeted TCR
therapy is the effective delivery of engineered reagents to
the tumor site. Such targeting of biologics has previously
been demonstrated in vivo employing molecular imaging
in both clinical and preclinical settings [48]. In particular,
fluorescence reflectance molecular imaging has typically
been employed preclinically owing to its high sensitivity
[49], low cost, and potential for rapid in vivo screening. A
major challenge for this strategy is to achieve sufficient
target-to-background ratios to evaluate specific targeting
over endogenous background auto-fluorescence and non-
specific binding. However, the density of specific MHC/
peptide complexes on the cell surface is usually low
(between 10 and 150 epitopes per cell) ([34] and unpub-
lished data), thwarting the use of TCRs in conventional
fluorescence imaging.
In contrast to conventional imaging, fluorescence life-
time or time-domain imaging can discriminate between
fluorophores with different lifetime decay rates [50]. Time-
domain optical imaging has been employed with great
success in distinguishing fluorescently labelled monoclonal
antibodies bound to target antigens from both auto-fluo-
rescence [41] and background fluorescence from unbound
antibodies [51]. In the current study, the administration of
three near-infrared-labelled TCR-NYEs of varying affini-
ties, combined with the use of time-domain optical imaging
techniques, confirmed targeting of the mTCRs to tumors
presenting the NY-ESO-1157–165 epitope.
To evaluate in vivo efficacy of ImmTAC-NYE, we
utilized NSG mice engrafted with human PBL in both
engraftment and established tumor models. We demon-
strated that a short course (5-day administration) of
ImmTAC-NYE substantially delayed engraftment of SK-
Mel-37-NY-ESO157–165 tumor cells, with tumors just detect-
able in treated mice 50 days post-implantation, while tumors
had reached an average volume of 368 mm3 in the control
treated mice. In an established tumor model using J82
tumor cells engineered to express NY-ESO157–165 and
GFP, we observed that five daily doses of ImmTAC-NYE
resulted in a significant reduction in GFP fluorescence
7 days post-initiation of therapy compared to control
treated mice, indicating a substantial reduction in tumor
cell viability. An issue with this particular cell line in vivo
was its inherent slow growth kinetics, which made differ-
entiation of therapeutic effect in this pilot study impossible
by calliper measurements. The significant reduction in
fluorescence demonstrated with only five doses of Imm-
TAC-NYE by time-domain optical imaging endorses both
application of this model and fluorescence lifetime gating
in further efficacy strategies.
In xenografted animal models which have investigated
ImmTAC efficacy (this study and [18]), inhibition of tumor
growth continues for long periods of time (over 5 weeks)
after the final dose of reagent. ImmTAC-activated T cells
release soluble factors including interferon-c, IL-2 and
TNFa (Fig. 1b), which can not only attract additional T
cells and other effector immune cells to the tumor site but
also promote components of the death receptor pathway in
the tumor cells [52], which can result in long-term anti-
tumor activity. In cancer patients, it is probable that
mechanisms such as epitope spreading (activation of
endogenous T cells specific for other tumor epitopes) will
occur, following cross-presentation of antigens from lysed
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tumor cells by dendritic cells. Indeed, we have demon-
strated cross-presentation induced by ImmTAC redirected
tumor cell killing in vitro (manuscript in preparation).
These mechanisms have the potential to stimulate a pro-
longed anti-tumor immune response capable of breaking
tumor tolerance. In addition, we have previously demon-
strated serial killing of several tumor cells by a single
ImmTAC-activated T cell, which may partly account for
the high potency of these reagents [18]. It is not known
whether the PBMC-engrafted mice have functioning den-
dritic cells and therefore whether cross-presentation and
epitope spreading can occur in this model system.
ImmTACs have been shown to detect low densities of
cell surface epitope (as few as 10 per cell), in contrast to
naturally occurring tumor-specific T cells which require
higher levels of target epitope to become activated [18].
Thus, ImmTACs have the potential to kill tumors which are
not recognized by low-avidity T cells in patients, for
example responses induced by cancer vaccines, since higher
avidity CTL specific for self-peptides have been removed by
negative thymic selection or inactivated by peripheral tol-
erance mechanisms. The ability of ImmTACs to detect a low
density of pMHCs and to activate immune cells indepen-
dently of co-receptors and other regulatory cells could cir-
cumvent immune tolerance in the tumor microenvironment
and overcome inhibitory mechanisms such as MHC down-
regulation or the presence of Tregs [8, 9]. Decreased levels
of MHC (relative to normal tissue cells) are frequently
observed in tumors, whereas complete loss of both chro-
mosomal loci encoding MHC and associated processing
machinery is a relatively rare event (unpublished observa-
tions and [53, 54]). Only patients with tumors positive for
both NY-ESO-1/LAGE-1 and HLA-A*0201 are eligible for
treatment with ImmTAC-NYE; we are currently isolating
NY-ESO-specific TCRs with different HLA restrictions, in
order to expand the target patient population. To conclude,
we have demonstrated specific and potent ImmTAC-NYE
redirected killing of NY-ESO-1 and LAGE-1 tumor cells
both in vitro and in vivo, supporting the clinical develop-
ment of this bi-specific reagent.
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